Approaches for measuring signalling plasticity in the context of resistance to targeted cancer therapies

Biochemical Society Transactions

Volumn 42, Issue 4, 2014, Pages 791-797

  Wilkes, Edmund H ^a   Casado, Pedro ^a   Cutillas, Pedro R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acquired resistance; Cancer; Mass spectrometry; Phosphoproteomics; Signalling plasticity; Systems biology

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; STAT5 PROTEIN; ANTINEOPLASTIC AGENT; PHOSPHOPROTEIN;

ANALYTIC METHOD; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CANCER CELL; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL SURVIVAL; CONFERENCE PAPER; FEEDBACK SYSTEM; GENETIC CONSERVATION; HUMAN; INTRACELLULAR SIGNALING; MOLECULARLY TARGETED THERAPY; NEGATIVE FEEDBACK; NONHUMAN; PLASTICITY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; DRUG RESISTANCE; GENETICS; MASS SPECTROMETRY; METABOLISM; NEOPLASM; PHYSIOLOGY; PROTEOMICS; SYSTEMS BIOLOGY;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MASS SPECTROMETRY; NEOPLASMS; PHOSPHOPROTEINS; PROTEOMICS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 84905861302     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20140029     Document Type: Conference Paper

References (50)

1. Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674
2. O'Hare, T., Zabriskie, M.S., Eide, C.A., Agarwal, A., Adrian, L.T., You, H., Corbin, A.S., Yang, F., Press, R.D., Rivera, V.M. et al. (2011) The BCR-ABL(35INS) insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood 118, 5250-5254
3. Boulos, N., Mulder, H.L., Calabrese, C.R., Morrison, J.B., Rehg, J.E., Relling, M.V., Sherr, C.J. and Williams, R.T. (2011) Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117, 3585-3595
4. Mok, T.S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y. et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957
5. Janku, F., Wheler, J.J., Westin, S.N., Moulder, S.L., Naing, A., Tsimberidou, A.M., Fu, S., Falchook, G.S., Hong, D.S., Garrido-Laguna, I. et al. (2012) PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J. Clin. Oncol. 30, 777-782
6. Fritsche-Guenther, R., Witzel, F., Sieber, A., Herr, R., Schmidt, N., Braun, S., Brummer, T., Sers, C. and Blüthgen, N. (2011) Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol. Syst. Biol. 7, 489
7. O'Reilly, K.E., Rojo, F., She, Q.B., Solit, D., Mills, G.B., Smith, D., Lane, H., Hofmann, F., Hicklin, D.J., Ludwig, D.L. et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508
8. Liu, Q., Xu, C., Kirubakaran, S., Zhang, X., Hur, W., Liu, Y., Kwiatkowski, N.P., Wang, J., Westover, K.D., Gao, P. et al. (2013) Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res. 73, 2574-2586
9. Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A.T., Thomas, G., Kozma, S.C. et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065-3074
10. Turke, A.B., Song, Y., Costa, C., Cook, R., Arteaga, C.L., Asara, J.M. and Engelman, J.A. (2012) MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 72, 3228-3237
11. Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., Bardelli, A. and Bernards, R. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103
12. Carver, B.S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V.K., Le, C., Koutcher, J., Scher, H. et al. (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575-586
13. Britschgi, A., Andraos, R., Brinkhaus, H., Klebba, I., Romanet, V., Mueller, U., Murakami, M., Radimerski, T. and Bentires-Alj, M. (2012) JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 22, 796-811
14. Garrett, J.T., Olivares, M.G., Rinehart, C., Granja-Ingram, N.D., Sánchez, V., Chakrabarty, A., Dave, B., Cook, R.S., Pao, W. and McKinely, E. (2011) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl. Acad. Sci. U.S.A. 108, 5021-5026
15. Guo, S.Q. and Sonenshein, G.E. (2004) Forkhead box transcription factor FOXO3a regulates estrogen receptor expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol. Cell. Biol. 24, 8681-8690
16. Tenbaum, S.P., Ordóñez-Morán, P., Puig, I., Chicote, I., Arqués, O., Landolfi, S., Fernández, Y., Herance, J.R., Gispert, J.D., Mendizabal, L. et al. (2012) β-Catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nature Medicine. 18, 892-901
17. Paraiso, K.H.T., Xiang, Y., Rebecca, V.W., Abel, E.V., Chen, Y.A., Munko, A.C., Wood, E., Fedorenko, I.V., Sondak, V.K., Anderson, A.R.A. et al. (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760
18. Casado, P., Rodriguez-Prados, J.-C., Cosulich, S.C., Guichard, S., Vanhaesebroeck, B., Joel, S. and Cutillas, P.R. (2013) Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. Sci. Signal. 6, rs6
19. Casado, P., Alcolea, M.P., Iorio, F., Rodríguez-Prados, J.-C., Vanhaesebroeck, B., Saez-Rodriguez, J., Joel, S. and Cutillas, P.R. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol. 14, R37
20. Ng, K.P., Hillmer, A.M., Chuah, C.T.H., Juan, W.C., Ko, T.K., Teo, A.S.M., Ariyaratne, P.N., Takahashi, N., Sawada, K., Fei, Y. et al. (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 18, 521-528
21. Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J. and Sawyers, C.L. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125
22. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N. and Sawyers, C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880
23. Kobayashi, S., Boggon, T.J., Dayaram, T., Janne, P.A., Kocher, O., Meyerson, M., Johnson, B.E., Eck, M.J., Tenen, D.G. and Halmos, B. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792
24. Yu, H.A., Arcila, M.E., Rekhtman, N., Sima, C.S., Zakowski, M.F., Pao, W., Kris, M.G., Miller, V.A., Ladanyi, M. and Riely, G.J. (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19, 2240-2247
25. Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S.P. et al. (2012) Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 18, 221-223
26. Sasaki, T., Koivunen, J., Ogino, A., Yanagita, M., Nikiforow, S., Zheng, W., Lathan, C., Marcoux, J.P., Du, J.Y., Okuda, K. et al. (2011) A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 71, 6051-6060
27. Choi, Y.L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H. et al. (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739
28. Wagle, N., Emery, C., Berger, M.F., Davis, M.J., Sawyer, A., Pochanard, P., Kehoe, S.M., Johannessen, C.M., MacConaill, L.E., Hahn, W.C. et al. (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096
29. Wagle, N., Van Allen, E.M., Treacy, D.J., Frederick, D.T., Cooper, Z.A., Taylor-Weiner, A., Rosenberg, M., Goetz, E.M., Sullivan, R.J., Farlow, D.N. et al. (2014) MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 4, 61-68
30. Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R.C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H. et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977
31. Montagut, C., Sharma, S.V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L.E., Dias-Santagata, D., Stubbs, H., Lee, D.Y., Singh, A. et al. (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853-4861
32. Poulikakos, P.I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M.T. et al. (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390
33. Ilic, N., Utermark, T., Widlund, H.R. and Roberts, T.M. (2011) PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl. Acad. Sci. U.S.A. 108, E699-E708
34. Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J. et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043
35. Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M. et al. (2011) Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 3, 99ra86
36. Girotti, M.R., Pedersen, M., Sanchez-Laorden, B., Viros, A., Turajlic, S., Niculescu-Duvaz, D., Zambon, A., Sinclair, J., Hayes, A., Gore, M. et al. (2013) Inhibiting EGF receptor or Src family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 3, 158-167
37. Villanueva, J., Vultur, A., Lee, J.T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A.K., Wubbenhorst, B., Xu, X.W., Gimotty, P.A., Kee, D. et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695
38. Jahangiri, A., De Lay, M., Miller, L.M., Carbonell, W.S., Hu, Y.-L., Lu, K., Tom, M.W., Paquette, J., Tokuyasu, T.A., Tsao, S. et al. (2013) Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin. Cancer Res. 19, 1773-1783
39. Xing, F., Persaud, Y., Pratilas, C.A., Taylor, B.S., Janakiraman, M., She, Q.B., Gallardo, H., Liu, C., Merghoub, T., Hefter, B. et al. (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 31, 446-457
40. Walsh, K., McKinney, M.S., Love, C., Liu, Q., Fan, A., Patel, A., Smith, J., Beaven, A., Jima, D.D. and Dave, S.S. (2013) PAK1 mediates resistance to PI3K inhibition in lymphomas. Clin. Cancer Res. 19, 1106-1115
41. Engelman, J.A., Chen, L., Tan, X., Crosby, K., Guimaraes, A.R., Upadhyay, R., Maira, M., McNamara, K., Perera, S.A., Song, Y. et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356
42. Workman, P., Al-Lazikani, B. and Clarke, P.A. (2013) Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Curr. Opin. Pharmacol. 13, 486-496
43. Kreeger, P.K. and Lauffenburger, D.A. (2010) Cancer systems biology: a network modeling perspective. Carcinogenesis 31, 2-8
44. Pe'er, D. and Hacohen, N. (2011) Principles and strategies for developing network models in cancer. Cell 144, 864-873
45. Beltran, L., Casado, P., Rodriguez-Prados, J.-C. and Cutillas, P.R. (2012) Global profiling of protein kinase activities in cancer cells by mass spectrometry. J. Proteomics 77, 492-503
46. Cutillas, P.R., Khwaja, A., Graupera, M., Pearce, W., Gharbi, S., Waterfield, M. and Vanhaesebroeck, B. (2006) Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 103, 8959-8964
47. Duncan, J.S., Whittle, M.C., Nakamura, K., Abell, A.N., Midland, A.A., Zawistowski, J.S., Johnson, N.L., Granger, D.A., Jordan, N.V., Darr, D.B. et al. (2012) Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307-321
48. Johnson, H., Del Rosario, A.M., Bryson, B.D., Schroeder, M.A., Sarkaria, J.N. and White, F.M. (2012) Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts. Mol. Cell. Proteomics 11, 1724-1740
49. Alcolea, M.P., Casado, P., Rodriguez-Prados, J.C., Vanhaesebroeck, B. and Cutillas, P.R. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol. Cell. Proteomics 11, 453-466
50. Cutillas, P.R. and Jorgensen, C. (2011) Biological signalling activity measurements using mass spectrometry. Biochem. J. 434, 189-199